Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053020 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT07053020: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07053020 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07053020, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of cladribine that can be given in combination with low dose cytarabine (LDAC) and venetoclax to patients who have AML. The goal of Part 2 of this clinical research study is to learn if the dose of cladribine found in Part 1, when combined with LDAC and venetoclax, can help to control the disease.
Interventions
- DRUG Cytarabine
- DRUG Oral Cladribine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2027-12-01 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07053020
The ClinicalTrials.gov registry entry for NCT07053020 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT07053020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07053020 about?
NCT07053020 is a clinical study titled "A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)". The goal of Part 1 of this clinical research study is to find the highest tolerable dose of cladribine that can be given in combination with low dose cytarabine (LDAC) and venetoclax to patients who have AML. The goal of Part 2 of this clinical research study is to learn if the dose of cladribine f...
What is the current status of trial NCT07053020?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2027-12-01. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT07053020?
The interventions under investigation include: Cytarabine (DRUG), Oral Cladribine (DRUG).
Who is sponsoring clinical trial NCT07053020?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.